全球血清型特异性肺炎球菌抗体反应指数（WISSPAR）：一个经过整理的临床试验数据库。
Worldwide Index of Serotype-Specific Pneumococcal Antibody Responses (WISSPAR): A curated database of clinical trial data.
作者信息
Perniciaro Stephanie, Cooper-Wooton Dominic, Knoll Maria, Weinberger Daniel
机构信息
Epidemiology of Microbial Diseases, Yale University, New Haven, Connecticut, USA.
International Vaccine Access Center, Department of International Health, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
Gates Open Res. 2023 Jul 13;7:109. doi: 10.12688/gatesopenres.14768.1. eCollection 2023.
Abstract
The Worldwide Index of Serotype Specific Pneumococcal Antibody Responses (WISSPAR; https://wisspar.com), is a centralized, online platform housing data on immunogenicity from clinical trials of pneumococcal vaccines. The data on WISSPAR are primarily curated from outcomes tables from clinical trials and are made available in a searchable format that can be readily used for downstream analyses. The WISSPAR database includes trials covering numerous vaccine products, manufacturers, dosing schedules, age groups, immunocompromised groups, and geographic regions. Customizable data visualization tools are embedded within the site, or the data can be exported for further analyses. Users can also browse summary information about the clinical trials and their results. WISSPAR provides a platform for analysts and policy makers to efficiently gather, compare, and collate clinical trial data about pneumococcal vaccines.
相似文献
1
Worldwide Index of Serotype-Specific Pneumococcal Antibody Responses (WISSPAR): A curated database of clinical trial data.全球血清型特异性肺炎球菌抗体反应指数（WISSPAR）：一个经过整理的临床试验数据库。
Gates Open Res. 2023 Jul 13;7:109. doi: 10.12688/gatesopenres.14768.1. eCollection 2023.
2
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力：系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
3
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.14 价肺炎球菌多糖结合疫苗（PNEUBEVAX 14™）在 6-8 周龄健康印度婴儿中的免疫原性和安全性：一项单盲、随机、阳性对照、III 期研究。
Vaccine. 2024 May 10;42(13):3157-3165. doi: 10.1016/j.vaccine.2024.03.056. Epub 2024 Apr 17.
4
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.在冈比亚健康婴儿中新型十价肺炎球菌结合疫苗的免疫原性和安全性：一项 3 期、随机、双盲、非劣效性试验。
Lancet Infect Dis. 2021 Jun;21(6):834-846. doi: 10.1016/S1473-3099(20)30735-0. Epub 2021 Jan 28.
5
Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study.给6至8周龄健康婴儿接种生物E公司14价肺炎球菌多糖结合疫苗（PNEUBEVAX 14）多人剂量制剂的免疫原性和安全性：一项3期、单盲、随机、活性对照研究。
Front Immunol. 2025 Apr 7;16:1550227. doi: 10.3389/fimmu.2025.1550227. eCollection 2025.
6
Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences.使用多变量加权估计在多血清型疫苗试验中简化处理差异的解释。
PLoS One. 2018 Apr 27;13(4):e0196200. doi: 10.1371/journal.pone.0196200. eCollection 2018.
7
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.免疫原性、中耳炎、听力损伤和 13 价或 10 价肺炎球菌结合疫苗加强免疫后 6 个月鼻咽携带率：PREVIX_COMBO 和 PREVIX_BOOST 随机对照研究。
Lancet Infect Dis. 2022 Sep;22(9):1374-1387. doi: 10.1016/S1473-3099(22)00272-9. Epub 2022 Jun 27.
8
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.21价肺炎球菌结合疫苗V116在健康成年人中的安全性、耐受性和免疫原性：1/2期、随机、双盲、活性对照、多中心、美国境内试验
Lancet Infect Dis. 2023 Feb;23(2):233-246. doi: 10.1016/S1473-3099(22)00526-6. Epub 2022 Sep 15.
9
Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: A systematic review and meta-analysis.临床研究中肺炎球菌结合疫苗免疫反应的地理区域差异的相关性：系统评价和荟萃分析。
Int J Infect Dis. 2020 Mar;92:261-268. doi: 10.1016/j.ijid.2019.12.021.
10
Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.含肺炎球菌蛋白的肺炎球菌结合疫苗制剂的免疫原性，以及同时接种常规疫苗的免疫原性和反应原性 - 冈比亚婴儿的 II 期、随机、观察者盲法研究。
Vaccine. 2019 May 1;37(19):2586-2599. doi: 10.1016/j.vaccine.2019.03.033. Epub 2019 Apr 8.
本文引用的文献
1
Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production.多价肺炎球菌结合疫苗在全球卫生领域的应用：从问题到平台再到生产。
Hum Vaccin Immunother. 2022 Nov 30;18(4):2117949. doi: 10.1080/21645515.2022.2117949. Epub 2022 Oct 14.
2
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.21价肺炎球菌结合疫苗V116在健康成年人中的安全性、耐受性和免疫原性：1/2期、随机、双盲、活性对照、多中心、美国境内试验
Lancet Infect Dis. 2023 Feb;23(2):233-246. doi: 10.1016/S1473-3099(22)00526-6. Epub 2022 Sep 15.
3
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.一项新型 24 价肺炎球菌疫苗在 18 至 64 岁健康成年人和 65 至 85 岁老年人中的 1/2 期研究。
Vaccine. 2022 Jul 29;40(31):4190-4198. doi: 10.1016/j.vaccine.2022.05.079. Epub 2022 Jun 9.
4
Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).下一代 24 价肺炎球菌结合疫苗（VAX-24）与当前标准治疗方法（PCV13 和 PPV23）的非临床免疫比较，使用了基于特定部位的载体蛋白偶联技术。
Vaccine. 2021 May 27;39(23):3197-3206. doi: 10.1016/j.vaccine.2021.03.070. Epub 2021 May 6.
5
Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.在结合疫苗时代儿童感染肺炎链球菌和乙型流感嗜血杆菌疾病的负担：2000-2015 年全球、区域和国家估计数。
Lancet Glob Health. 2018 Jul;6(7):e744-e757. doi: 10.1016/S2214-109X(18)30247-X.
6
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.13 价肺炎球菌结合疫苗的血清型特异性效力和保护相关性：上市后间接队列研究。
Lancet Infect Dis. 2014 Sep;14(9):839-46. doi: 10.1016/S1473-3099(14)70822-9. Epub 2014 Jul 17.
7
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.用于预防2岁以下儿童疫苗型侵袭性肺炎球菌疾病和X线确诊肺炎的肺炎球菌结合疫苗。
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004977. doi: 10.1002/14651858.CD004977.pub2.
Zotero 插件